Asymmetric dimethylarginine (ADMA): the silent transition from an 'uraemic toxin' to a global cardiovascular risk molecule. - Test2 - elhamkhani - TriplyDB

Asymmetric dimethylarginine (ADMA): the silent transition from an 'uraemic toxin' to a global cardiovascular risk molecule.

Asymmetric dimethylarginine (ADMA): the silent transition from an 'uraemic toxin' to a global cardiovascular risk molecule.

http://www.wikidata.org/entity/Q36018553

about

Characterization of C-Alkyl Amidines as Bioavailable Covalent Reversible Inhibitors of Human DDAH-1 Serum methylarginines and spirometry-measured lung function in older adults L-Arginine supplementation or arginase inhibition augments reflex cutaneous vasodilatation in aged human skin.[Thrombocytopathy and blood complications in uremia].Cerebral changes occurring in arginase and dimethylarginine dimethylaminohydrolase (DDAH) in a rat model of sleeping sickness Dimethylarginine metabolism during acute and chronic rejection of rat renal allografts Evaluation of microvascular reactivity with laser Doppler flowmetry in chronic kidney disease Emerging role of epoxyeicosatrienoic acids in coronary vascular function.Endogenous inhibitors of nitric oxide and preeclampsia: a review.ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction.Impact of Continuous Erythropoietin Receptor Activator on Selected Biomarkers of Cardiovascular Disease and Left Ventricle Structure and Function in Chronic Kidney Disease.Nitric oxide and L-arginine metabolism in a devascularized porcine model of acute liver failure.Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease.Endothelial function in patients with familial Mediterranean fever-related amyloidosis and association with cardiovascular events.Metabolomic Profiling of Arginine Metabolome Links Altered Methylation to Chronic Kidney Disease Accelerated Atherosclerosis.Comprehensive assessment of nephrotoxicity of intravenously administered sodium-oleate-coated ultra-small superparamagnetic iron oxide (USPIO) and titanium dioxide (TiO2) nanoparticles in rats.Relation between asymmetric dimethylarginine (ADMA) and hearing loss in patients with renal impairment.Asymmetrical dimethylarginine plasma clearance persists after acute total nephrectomy in rats.Concentrations of representative uraemic toxins in a healthy versus non-dialysis chronic kidney disease paediatric population.Accumulation of uraemic toxins is reflected only partially by estimated GFR in paediatric patients with chronic kidney disease.Contribution of whole blood to the control of plasma asymmetrical dimethylarginine.Asymmetric dimethyl-arginine and coronary artery calcification in young adults entering middle age: the CARDIA Study.Biological variation of asymmetric dimethylarginine and related arginine metabolites and analytical performance goals for their measurement in human plasma.ADMA correlates with portal pressure in patients with compensated cirrhosis.

P2860

Q27665385-07ED2CA6-EE65-4731-BB34-ADA799C939A2 Q28488125-42653B08-02E3-45C6-8ADD-29F8EBB764B2 Q33242325-9F857D0F-142C-416C-B226-6F2EC0B3A8A1 Q33371562-08189A82-7F83-49A0-8129-A2159E18DBDE Q33847194-FC111CED-E9B2-4B19-9335-174608A78D53 Q34426973-05A333B9-6CB4-402F-9372-C627E080A1B8 Q35047495-00E16E41-1435-4B8C-A418-E5CF715121B8 Q36458500-B5F13BF0-CECA-46D9-9136-2DBA43A27710 Q36590924-5130673F-BD86-4BC9-9A9E-9F485F07B01F Q36677348-E51C3CC1-15D6-42E1-968A-AA0212B5111E Q36681249-7EC404B5-7E0B-4695-933C-AC33320B58CC Q37174684-8E1E1320-6AC4-4FE1-9B61-2971BC3B072A Q38853235-69B58CDC-A8F0-4DCC-9433-E605870F06F5 Q40204455-111A8902-FE99-4574-95E9-85F635F02DB9 Q41979223-E430623F-D4ED-413D-ACEE-79A305ECB966 Q43465717-EB607AD7-23AA-4163-B146-B08C52E61180 Q46313782-0A59AB55-6CCE-42D6-8DA7-01F8AD5989EC Q46661250-B720C87D-4138-48E5-99FA-E99F309ACB1D Q47676937-DB96A1BF-A985-48C4-98D8-6F14D688C675 Q47676953-B2804EA7-55BF-4660-B408-2991DBFE783C Q50736531-61391F97-671D-4EA0-ADD7-3AE6546C0333 Q51756269-C7014CE1-20F8-47E8-B141-B7D5EDD4C7DA Q53021614-4FBFD023-D490-40CD-B0D0-42710A0E3C25 Q54312440-730E47F5-BEB7-425A-8309-D65D079E3771

P2860

Asymmetric dimethylarginine (ADMA): the silent transition from an 'uraemic toxin' to a global cardiovascular risk molecule.

http://www.wikidata.org/entity/Q36018553

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Asymmetric dimethylarginine (A ...... cardiovascular risk molecule.

@ast

Asymmetric dimethylarginine (A ...... cardiovascular risk molecule.

@en

type

label

Asymmetric dimethylarginine (A ...... cardiovascular risk molecule.

@ast

Asymmetric dimethylarginine (A ...... cardiovascular risk molecule.

@en

prefLabel

Asymmetric dimethylarginine (A ...... cardiovascular risk molecule.

@ast

Asymmetric dimethylarginine (A ...... cardiovascular risk molecule.

@en

P1433

Q36018553-376554E5-6D5B-4B2A-B1FF-97F4DAC7B3BC

P1476

Q36018553-66093F7B-504A-458F-A3E5-6A97C57AA006

P2093

Q36018553-3BC51208-BD5D-4EF3-983D-99FAE08B9919

P2860

Q36018553-00BE4B07-513C-4338-8CBF-61D7C577EB9B

Q36018553-04C89B2E-EE04-4E06-A52B-15717D6AF48E

Q36018553-098BB4A2-B7F3-44C7-BAB1-67D450A2E11B

Q36018553-09C0EB21-8A4B-4594-8DFB-5CB355D55F45

Q36018553-0A11C2DB-9FB5-4275-B5B0-C7D75BF6D978

Q36018553-0B5DEEEB-4C17-4C23-A93C-D55FB7276E85

Q36018553-11895BD0-5054-48C6-872B-0174BD4D9967

Q36018553-14147B35-ABD2-4092-8311-F0E197E77F21

Q36018553-16B2B244-497F-4EB1-BE94-AF44A9556C59

Q36018553-18714A20-E0DD-47D7-85F4-1D8F407EEE79

P304

Q36018553-AF22DF0A-2964-4F08-BC8A-10DD72909D3B

P31

Q36018553-8B3F171D-FA78-4268-8F0D-0F04DD45917B

P356

Q36018553-A295CFF1-3481-4974-810F-182701BF5FEB

P433

Q36018553-01BBDB0E-30DF-49F7-B15D-0C8BA1FEE27C

P478

Q36018553-D850998C-F2B2-4ABE-820B-2DB3B1F42286

P577

Q36018553-FD9A10DA-08D2-4D2C-908F-B0206DBDFED2

P5875

Q36018553-82C40B6D-3D28-4B65-916A-324D764A1049

P698

Q36018553-183CD832-259C-413D-B83A-3BF1D22A0496

P921

Q36018553-E6C25DD8-C290-4239-B70A-33C71E75CF00

P356

J.1365-2362.2005.01457.X

P1433

European Journal of Clinical Investigation

P1476

Asymmetric dimethylarginine (A ...... cardiovascular risk molecule.

@en

P2093

Fliser D

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases

Protein-arginine methyltransferase I, the predominant protein-arginine methyltransferase in cells, interacts with and is regulated by interleukin enhancer-binding factor 3

The L-arginine-nitric oxide pathway

S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase

Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase

LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases

Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease

Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension

Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon: implications for vascular dysfunction and progression of disease.

Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase.

P304

71-79

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2362.2005.01457.X

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P577

2005-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8063306

http://www.w3.org/2001/XMLSchema#string

P698

15667575

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio